Loading clinical trials...
Loading clinical trials...
The objective of this study is to find out the biochemical markers which have independent predictive value of fragility fractures risk with Type 2 diabetes in Guangzhou community and evaluate bone strength better and increase the ability of recognizing fracture risk through following-up visits the bone metabolism index like esRAGE-to-pentosidine ratio of the petients with type 2 diabetes and osteoporosis,compared with the classical fracture risk assessment instrument.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Baiyun Community Taihe Town
Guangzhou, Guangdong, China
Guangzhou No.12 People's Hospital
Guangzhou, Guangdong, China
Haizhu Changgang Community
Guangzhou, Guangdong, China
Tianhe Community
Guangzhou, Guangdong, China
Zhujiang Hospital
Guangzhou, Guangdong, China
Start Date
July 1, 2017
Primary Completion Date
November 30, 2021
Completion Date
December 31, 2021
Last Updated
March 21, 2022
99
ACTUAL participants
OTHER
Lead Sponsor
Zhujiang Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions